IDEXX LABORATORIES INC
NASDAQ: IDXX (IDEXX Laboratories, Inc.)
Last update: 1 hour ago460.01
-3.88 (-0.84%)
| Previous Close | 463.89 |
| Open | 466.60 |
| Volume | 539,085 |
| Avg. Volume (3M) | 469,365 |
| Market Cap | 37,861,539,840 |
| Price / Earnings (TTM) | 45.68 |
| Price / Earnings (Forward) | 40.98 |
| Price / Sales | 10.27 |
| Price / Book | 24.16 |
| 52 Weeks Range | |
| Earnings Date | 31 Oct 2024 |
| Profit Margin | 22.34% |
| Operating Margin (TTM) | 32.41% |
| Diluted EPS (TTM) | 10.07 |
| Quarterly Revenue Growth (YOY) | 6.40% |
| Quarterly Earnings Growth (YOY) | -9.30% |
| Total Debt/Equity (MRQ) | 67.58% |
| Current Ratio (MRQ) | 1.37 |
| Operating Cash Flow (TTM) | 969.18 M |
| Levered Free Cash Flow (TTM) | 816.01 M |
| Return on Assets (TTM) | 22.77% |
| Return on Equity (TTM) | 63.25% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Mixed |
| Diagnostics & Research (Global) | Bullish | Mixed | |
| Stock | IDEXX Laboratories, Inc. | Bearish | Bullish |
Stockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.13 |
|
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.94% |
| % Held by Institutions | 95.99% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Blair William & Co/Il | 30 Jun 2024 | 1,173,058 |
| Fundsmith Investment Services Ltd. | 30 Jun 2024 | 863,162 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 580.00 (BTIG, 26.08%) | Buy |
| Median | 547.50 (19.02%) | |
| Low | 500.00 (Stifel, 8.69%) | Hold |
| Average | 543.75 (18.20%) | |
| Total | 2 Buy, 2 Hold | |
| Avg. Price @ Call | 473.79 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 11 Oct 2024 | 575.00 (25.00%) | Buy | 476.27 |
| Stifel | 10 Oct 2024 | 500.00 (8.69%) | Hold | 473.28 |
| Piper Sandler | 14 Aug 2024 | 520.00 (13.04%) | Hold | 474.94 |
| BTIG | 25 Jul 2024 | 580.00 (26.08%) | Buy | 470.68 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 30 Sep 2024 | Announcement | IDEXX Laboratories to Release 2024 Third Quarter Financial Results |
| 21 Aug 2024 | Announcement | IDEXX Laboratories to Present at Morgan Stanley 22nd Annual Global Healthcare Conference |
| 06 Aug 2024 | Announcement | IDEXX Laboratories Announces Second Quarter Results |
| 30 Jul 2024 | Announcement | IDEXX Releases 2023 Corporate Responsibility Report, Highlighting Progress Against Its Goals |
| 30 Jul 2024 | Announcement | IDEXX Laboratories Announces Time Change for 2024 Second Quarter Financial Results Conference Call |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |